electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
21 March 2023 - 11:00PM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine and wellness company, today
announced the results of a TruvagaTM focus group study conducted
earlier this year. Based on a 30-day in-home use test by an
independent third-party research firm, the Truvaga product helped
its users improve stress, anxiety, sleep, energy, and mood.In the
in-home focus group study, 34 participants were instructed to use
the Truvaga product twice a day for 30 days to assess the product's
benefits and overall user experience. Self-assessment evaluations
were reported after 7 and 30 days. After 30 days, users reported
the following:
- 94% felt calmer;
- 91% felt their mood improved;
- 88% felt less anxious;
- 85% felt an improvement in stress;
- 82% felt more alert;
- 77% had more energy; and
- 74% felt they sleep better.
“My sleep was horrible before using this device as was my stress
and anxiety,” said Diane G. a study participant. “To be honest, I
really didn't think a device that I use on my neck would change
either of those problems. Well, I am wrong and a little embarrassed
because my sleep has not been this good in 20 years. I am finding
my stress to be very minimal as well and so are others in my
everyday life. My sleep is such a healthy part of my life now and I
am sleeping all night, waking easily and well rested. I’m
completely blown away by how much this device has turned my life
completely around by using it just twice a day.”After the study was
completed, 86% of users said they will continue to use the product
for ongoing overall wellness benefits.“I am thrilled about the
initial launch of our wellness product, Truvaga,” stated Michael
Mansfield, VP, Marketing at electroCore. “The initial response and
testimonials we received are a reminder of the benefits that can be
realized by using vagus nerve stimulation and I look forward to
building the Truvaga brand during 2023 through ecommerce and
affiliate channels.”Results of the focus group study can be found
on our website, www.truvaga.com.About electroCore,
Inc.electroCore, Inc. is a commercial stage bioelectronic
medicine and wellness company dedicated to improving health through
its non-invasive vagus nerve stimulation (“nVNS”) technology
platform. Our focus is the commercialization of medical devices for
the management and treatment of certain medical conditions and
consumer product offerings utilizing nVNS to promote general
wellbeing and human performance in the United States and select
overseas markets.For more information, visit
www.electrocore.com.About TruvagaTMTruvaga is a
break-through handheld vagus nerve stimulator that utilizes our
proven technology to quickly and gently activate the vagus nerve.
It’s designed to work with the body to balance the nervous system
to feel calmer, think clearer, and sleep better.For more
information, please visit www.truvaga.com.Forward-Looking
StatementsThis press release and other written and oral
statements made by representatives of electroCore may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements about
electroCore's business prospects, wellness product offerings, new
ecommerce site, and clinical and product development plans; its
pipeline or potential markets for its technologies; the timing,
outcome and impact of regulatory, clinical and commercial
developments including focus group study results; the Company’s
business prospects in the United States (including its e-commerce
initiatives) and other new markets and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "will," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, the potential impact and
effects of COVID-19 on the business of electroCore, electroCore’s
results of operations and financial performance, and any measures
electroCore has and may take in response to COVID-19 and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.Investors:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024